Allison Swartz Sells 1,199 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 1,199 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the sale, the executive vice president directly owned 83,316 shares of the company’s stock, valued at approximately $2,084,566.32. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Thursday, June 4th, Allison Swartz sold 599 shares of Progyny stock. The shares were sold at an average price of $25.08, for a total value of $15,022.92.

Progyny Stock Performance

NASDAQ:PGNY opened at $25.86 on Friday. The firm has a market cap of $2.03 billion, a PE ratio of 33.58, a price-to-earnings-growth ratio of 2.28 and a beta of 1.03. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75. The business has a 50 day moving average price of $20.58 and a 200-day moving average price of $22.30.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The firm had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Research analysts predict that Progyny, Inc. will post 1.07 EPS for the current year.

Progyny announced that its board has authorized a share repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PGNY. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Truist Financial upped their target price on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, May 11th. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and upped their target price for the company from $19.00 to $30.00 in a report on Tuesday, May 19th. Citigroup restated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Finally, Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $29.67.

Hedge Funds Weigh In On Progyny

A number of institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its holdings in Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares in the last quarter. Teza Capital Management LLC raised its holdings in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares in the last quarter. Leibman Financial Services Inc. raised its holdings in Progyny by 1.2% in the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock worth $1,192,000 after purchasing an additional 528 shares in the last quarter. Aristides Capital LLC raised its holdings in Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after purchasing an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP raised its holdings in Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.